DOT1L and neoplasm: High DOT1L expression has been found in a number of nonhematologic neoplasms including breast (Lee and Kong, 2015; Nassa et al., 2019), prostate (Annala et al., 2014), ovarian, gastric cancer (Wang X. et al., 2019), and other malignancies (Figure 1).